XXXX : The Relevance of a Combined Dexamethasone Desmopressin Test as a Component of Postoperative Hormonal Evaluation.

@entity1 @entity619 @entity701 @entity699
UNASSIGNED: Background. The risk of @entity699 ( @entity699 ) recurring may persist for years, even after initially successful surgery. Objective. To prospectively assess the relevance of a combined @entity619 desmopressin test (CDDT) as a component of postoperative hormonal evaluation, including the dynamics of ACTH and @entity701 concentrations. Material and Methods. We included 28 @entity1 after TSS for @entity699 . Eighteen months after surgery the standard hormonal evaluation was performed, followed by a CDDT. Results. Fifteen @entity1 (53.6%) were in remission whereas in 13 subjects (46.4%) hypercortisolemia was confirmed. Positive results of CDDT were observed in 12 noncured @entity1 (92.3%) and in one subject in remission (6.7%). Negative results were obtained in 12 @entity1 with remission (80%) and in one noncured @entity1 (7.7%). With 2 @entity1 in @entity699 remission (13.3%) the test results were inconclusive. We confirmed a high compatibility between CDDT and standard hormonal assessment results (k = 0.846; P < 0.001). Significant differences in ACTH and @entity701 levels at each CDDT time point between the two studied subgroups were shown. Conclusions. A negative CDDT result can be regarded as one of the factors indicative of @entity699 remission during follow-up. Additionally, CDDT can help distinguish persistent hypercortisolemia from naturally recurring adrenal function after TSS.
